Table 1.
Clinicopathological characteristic of subjects and correlation between serum CA 15–3 and CEA level and clinicopathological factors.
Fig 1.
Kaplan-Meier survival curves of patients with normal or elevated CEA and CA15-3 levels.
Disease-free survival (DFS) according to carcinoembryonic antigen (CEA) (A) and cancer antigen 15–3 (CA15-3) (B). Overall survival (OS) according to CEA(D) and CA15-3(E). DFS according to the combination of both marker levels(C) and OS according to the combination of both marker levels (F).
Table 2.
Univariate analysis of prognostic factors for survival time of breast cancer patients.
Table 3.
Multivariate Cox’s regression analysis according to tumor size,nodal status, stage, HER2 status, and serum tumor markers.
Fig 2.
Kaplan-Meier survival curves of Luminal B breast patients with normal or elevated CEA and CA15-3 levels.
DFS according to CEA(A) and CA15-3(B), OS according to CEA(C) and CA15-3(D).